p63, a p53 homolog has been shown to play a role in development and cancer. p63 is essential for both commitment of ectoderm to stratified epithelia and for the proliferative potential of epithelial stem cells. p63 knockout mice are born with severe development defects and lack organs of epithelial origin. In addition, p63 has also been shown to play a role in cancer development through the differential regulation of genes with tumor suppressor function and genes involved in metastasis. In order to understand the role of p63 in cancer and development, genes that are specifically regulated by p63 but not p53 were identified. In this study, we provide evidence that p63c specifically upregulates vitamin D Receptor (VDR). In contrast, p53 does not appear to be involved in upregulation of VDR expression. Additionally, we demonstrate that a naturally occurring p63 missense mutant, p63c (R279H) and p14 ARF , both act in a dominant negative manner to inhibit p63c-mediated upregulation of VDR. Furthermore, using chromatin immunoprecipitation assays, we demonstrated that p63 directly binds to the VDR promoter in vivo. Our findings clearly demonstrate that VDR is a direct target of p63 and suggests that p63 may play a role in cancer and differentiation through modulation of the VDR pathway. Oncogene (2006 Oncogene ( ) 25, 3745-3751. doi:10.1038 published online 6 February 2006 Keywords: p63g; VDR; p14 ARF ; differentiation
The three members of the p53 family, p53, p63 and p73, share high homology and all contain a transactivation domain, a DNA binding domain and an oligomerization domain. The various forms of p63 have high homology to p53 within their amino terminal transactivation domain (B25%), oligomerization domains (B35%) and DNA binding domain (B65%). Owing to structural similarity between p63 and p53, p63 can bind to p53 DNA consensus sequences to activate transcription of p53-inducible genes such as Mdm2, Bax, p21 and 14-3-3s, independent of p53 status and induce apoptosis when overexpressed in cells (Osada et al., 1998; Yang et al., 1998; Shimada et al., 1999) . Unlike p53, which encodes a single polypeptide, the gene structure for p63 is complex. To date six different alternatively spliced isoforms of p63 have been identified p63a, p63b, p63g, DNp63a, DNp63b and DNp63g based on promoter usage and variable carboxy-termini resulting in considerably different activities as transcription factors (Yang et al., 1998) . Three of the six isoforms, p63a, p63b, and p63g encode proteins that contain the transactivation (TA), DNA binding and oligomerization domains whereas the DNp63a, DNp63b and DNp63g isoforms lack the N-terminal transactivation domain (Yang et al., 1998) . p63g has been shown to be the potent transactivator and an inducer of apoptosis as compared to p63a (Osada et al., 1998; Yang et al., 1998; Shimada et al., 1999) . p63 is essential for limb, craniofacial and epidermal morphogenesis and is expressed specifically in the embryonic ectoderm that gives rise to progenitor cells of the epidermis (Mills et al., 1999; Yang et al., 1999) . Initiation and execution of the epithelial stratification program involves sequential activation of the TAp63 isoform followed by the DNp63 isoform (Mills et al., 1999; Yang et al., 1999) . This demonstrates that p63 is essential not only for commitment of ectoderm to stratified epithelia but also for proliferative potential of epithelial stem cells. Epithelial stem cells have been shown to be involved in progression of prostate cancer (Hudson, 2004) . p63 isoforms containing the TA domain has been shown to limit tumor progression by inducing expression of insulin growth factor binding protein-3 (IGFBP-3, an apoptotic gene), and inhibiting the expression of vascular endothelial growth factor (VEGF, a gene known to play an important role in angiogenesis and neovascularization), and heat shock protein 70 (HSP70, an antiapoptotic gene) (Senoo et al., 2002; Wu et al., 2003; Barbieri et al., 2005) . In contrast, DNp63 isoforms of p63 lacking the TA domain represses the expression of IGFBP-3 and induces expression of HSP70 and VEGF thus protecting tumors overexpressing DNp63 isoforms from apoptosis. Expression of Maspin, a tumor suppressor gene, has also been shown to be positively regulated by p63 in lung cancer specimens (Kim et al., 2004; Spiesbach et al., 2005) . Similarly, both Jagged 1 and Jagged 2, ligands of the Notch receptor known to play a role in tumor development, are specifically induced by p63 but not p53 (Sasaki et al., 2002a) . Similar to p53, p63 has also been shown to activate major apoptosis pathways by triggering signaling via death receptors and the mitochondria (Gressner et al., 2005) . Endogenous p63 has been shown to be induced by many chemotherapeutic agents and blocking this function might confer chemoresistance (Petitjean et al., 2005) . Thus, it seems that while DNp63 isoforms of p63 act as an oncogene, p63 isoforms containing the TA domain can perform tumor suppressor activities by the differential regulation of a variety of genes as mentioned above.
Although the reports described above emphasize the contrasting functions of TAp63 and DNp63 isoforms during development and cancer, additional studies are needed to decipher the signaling pathways regulated by p63 during development. In an effort to identify the downstream targets of p63, we analysed the gene expression profile of H1299 cells transiently transfected with p63g using Affymetrix-based oligonucleotide arrays representing 12 625 genes. Table 1 lists a subset of genes significantly upregulated by p63g. As shown in Table 1 , we identified genes, such as p21, PIG3, Mdm2, 14-3-3s and IGFBP-3 which are known targets of p53 but also known to be regulated by p63. This result not only validates previous observations that p63 can regulate p53 specific targets but also serve as positive controls for the gene expression profile results obtained in this study. In addition, other previously identified targets of p63 such as JAG2, NOTCH3, SMARCD3 were also shown to be upregulated by p63 (Sasaki et al., 2002b; Osada et al., 2005) . Interestingly, we observed the upregulation of the vitamin D receptor (VDR) suggesting that p63 might regulate VDR pathway. Additionally, both p21 and IGFBP-3 are known downstream targets of the VDR pathway.
VDR is a ligand dependent transcription factor, which belongs to a nuclear receptor family. 1,25 dihydroxy vitamin D3 (VD) and its analogues are used as chemotherapeutic agents for the treatment of prostate cancer (Miller, 1998; Blutt and Weigel, 1999; Konety et al., 1999; Feldman et al., 2000) . VD mediates its biological activities through VDR, which upon ligand activation heterodimerizes with retinoid X receptor and regulates the expression of genes via vitamin D responsive element (VDRE) present in the promoters of responsive genes. VDR primarily regulates the expression of genes involved in calcium homeostasis and differentiation (Banerjee and Chatterjee, 2003; Christakos et al., 2003; Guzey et al., 2004) . VDR is expressed in the basal layers of keratinocytes and plays an important role in regulating the differentiation and proliferation of epidermal cells (Xie et al., 2002; Bikle, 2004; Bikle et al., 2004) . Recently, VDR was shown to regulate genes known to play a role in differentiation of keratinocytes by binding directly to its cognate binding sites on promoter regions (Bikle et al., 2003; Lu et al., 2005) . Since both p63 and VDR are known to be involved in differentiation, we wanted to investigate whether p63 regulates VDR expression.
First, we validated the expression of VDR by TaqMan-based Reverse Transcriptase PCR analysis in two different cell lines. Both H1299 and HeLa cells were transfected with p63g, p53 and control vector ( Figure 1a) . At 24 h post-transfection, a significant upregulation of VDR gene expression was observed in cells transfected with p63g (lane 2) whereas cells transfected with p53 did not upregulate VDR expression in either of the cell lines tested (lane 3). Immunoblot analysis on whole cell extracts prepared from H1299 and HeLa cell lines transiently transfected with p63g exhibited a significant increase in VDR protein levels as compared with control vector or p53 transfected cells ( Figure 1b) . As a positive control, we examined expression of p21, a target of both p53 and p63. We observed that both p63g and p53 upregulated the expression of p21 at the transcript as well as protein level ( Figure 1a , lower panel and Figure 1b ). To further investigate whether p63 transcriptionally upregulates VDR, we constructed a VDR-Luc reporter by cloning the VDR promoter region into the pGL3-Basic promoter-less plasmid (Miyamoto et al., 1997) . H1299 and HeLa cells transfected with p63g showed a significant increase in VDR-Luc reporter activity as compared to cells transfected with control vector or p53 ( Figure 1c , lane 2). Together these results demonstrate that p63g specifically upregulates VDR expression independent of p53 status.
Recently p14 ARF has been shown to inhibit p63-mediated transactivation of p53 responsive genes (Calabro et al., 2004) but little is known about its effect on p63 specific target genes. We examined whether p14 ARF can inhibit p63-mediated upregulation of VDR (Figure 2 ). We observed that p63g-mediated VDR expression ( Figure 2a ARF also led to inhibition of p63g-mediated activation of p21. Additionally, a decrease in protein levels of VDR and p21 was observed in cells co-transfected with p63g and p14 ARF (Figure 2b ). These results are further supported by the observation that p14 ARF inhibited p63-mediated transactivation of VDR-Luc reporter activity (Figure 2c ). Thus, p14
ARF exerts differential effects on p53 and p63, both members of the p53 family. While p14 ARF increases p53-mediated transactivation by sequestering Mdm2, a negative regulator of p53, p14 ARF Identification of vitamin D receptor as a target of p63 R Kommagani et al exerts its inhibitory effect on p63 by binding to its transactivation domain (Pomerantz et al., 1998; Honda and Yasuda, 1999; Zhang and Xiong, 1999; Calabro et al., 2004) . Mutations in p63 have been observed in various human developmental syndromes (Barrow et al., 2002; Brunner et al., 2002a, b; van Bokhoven and McKeon, 2002) . The p63g (R279H) point mutant has been identified in EEC syndrome and this missense mutation is localized to the critical DNA binding domain of p63 (Celli et al., 1999; South et al., 2002) . Interaction of p63 mutants with wild-type p63 can lead to inhibition of transcriptional activity and subsequently result in loss of biological functions, such as growth arrest, apoptosis and differentiation. This can occur through proteinprotein interactions in the oligomerization domain present in p63. Thus, the formation of heterotetramers leads to a dominant negative phenotype. Co-transfection of p63g (R279H) along with p63g, led to a significant inhibition of p63g-mediated upregulation of VDR expression (Figure 3a) . p63g (R279H) also inhibited p63g-mediated upregulation of p21, a known p63 target, although its effect was not as potent as that seen on VDR expression. Inhibition of p63g-mediated upregulation of VDR and p21 by the p63g (R279H) mutant protein results in reduced proteins levels as well (Figure 3b) . Finally, we observed that p63g (R279H) inhibits p63g-mediated VDR-Luc reporter activity in a dose dependent manner (Figure 3c , lanes 4 and 5). p63g (R279H) mutant over expression by itself had no effect on VDR expression (Figure 3a and b, lanes 4) or VDR reporter activity (Figure 3c, lane 3) . Together these results suggest that the naturally occurring p63 missense mutant acts in a dominant negative manner to specifically inhibit p63 specific target genes. Inhibition of p63-mediated VDR transactivation by both p14 ARF and the p63 missense mutant indicates that p63 is involved in the activation of VDR expression.
We further demonstrated that p63 binds to the VDR promoter in vivo using Chromatin immunoprecipitation (ChIP) assay. For the ChIP assay, H1299 cells were transiently transfected with either p63g or p53 expression plasmids. Formaldehyde cross-linked chromatin was immunoprecipitated with polyclonal rabbit antibodies to either anti-p63 for p63g transfected cells or anti-p53 for p53 transfected cells. Normal rabbit IgG antibody was used as a negative control for nonspecific binding during immunoprecipitation. The eluted DNA was subjected to PCR amplification using primers specific for VDR promoter and 14-3-3s promoter. Nonimmunoprecipitated cross-linked DNA (input) was used as positive control for confirming the size of the PCR amplified product. As shown in Figure 4a , amplification of the VDR promoter region was observed in cells transfected with p63g, demonstrating that p63g At 24 h post-transfection, total protein was extracted form cells using RIPA buffer (0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS, phosphate buffered saline, pH 7.4). Whole cell lysates were resolved on 10% SDS gel and endogenous VDR and p21 protein levels were detected by using anti-VDR (Santa Cruz Biotechnoloy) and anti-p21 (Santa Cruz Biotechnoloy) antibodies. Immunoblot analysis was also performed to confirm the over expression of p63 and p53 using anti-p63 (4A4, Santa cruz biotech) and anti-p53 (Calbiochem, San Diego, CA) antibodies. Immunoblotting for bactin was performed to confirm equal protein loading. Identification of vitamin D receptor as a target of p63 R Kommagani et al binds to the VDR promoter region. In contrast, no amplification of the VDR promoter region was observed in cells transfected with p53 indicating that p53 does not bind to the VDR promoter. This is not surprising since p53 does not appear to activate VDR expression (Figure 1) . Amplification of 14-3-3s, a target of both p63 and p53 gene was performed as positive control Immunoblot analysis was performed to confirm the overexpression of p63 and p14 ARF proteins using p63 and p14 ARF specific antibodies. Immunoblot analysis performed by resolving equal amounts of protein on 10% SDS gel. Endogenous VDR and p21 protein levels were detected by using VDR and p21-specific antibodies. Over expression of both wild-type p63g and mutant p63g (R279H) was confirmed by using a p63 specific antibody. 
Identification of vitamin D receptor as a target of p63
R Kommagani et al since both p63 and p53 have been shown to bind to 14-3-3s promoter (Westfall et al., 2003) . These results demonstrate that p63 binds to the VDR promoter in vivo. Detailed analysis of the promoter region of p63 responsive genes has resulted in the identification of responsive elements that are specifically activated by p63 (Osada et al., 2005; Sasaki et al., 2005) . The p63 responsive element appears to differ from the canonical (RRRCWWGYYY) responsive element of p53 in the CWWG core binding element as well as in the flanking RRR and YYY stretches (Osada et al., 2005) . The nucleotide G in the fifth position, instead of a W, within the core along with a number of mismatches in the flanking RRR and YYY sequence was found to distinguish the p63 responsive elements from that of p53 (Osada et al., 2005) . Furthermore, p63 was also shown to activate responsive elements containing CGTG as the core-binding element. Examination of the 1500 bp VDR promoter region revealed the presence of several possible p63 responsive elements that could serve as binding sites for p63. In order to define the region within the VDR promoter required for p63g-induced transactivation, we constructed a series of promoter deletions distal to the transcriptional start site. H1299 cells were transfected with the various promoter deletions alone or along with the p63g expression plasmid (Figure 4b) . We observed that the deletion of first 736 nucleotides from the 5 0 end (À1500 to À765) did not abolish the promoter activity. Interestingly the region between À631 and À585 was found to contain putative p63 binding elements based on sequence analysis of Osada et al. (2005) . We subsequently cloned region À631 to À585 of the VDR promoter into the PGL3 promoter-less reporter plasmid and determined the promoter activity in presence of p63g (Figure 4b , lower panel). We observed that p63g led to a significant increase in the À631/À585 reporter Figure 4 p63g binds to VDR promoter in vivo and promotes differentiation. (a) For ChIP analysis, H1299 cells were transfected with p63g or p53 expression plasmids. At 24 h post-transfection cells were harvested. ChIP analysis was performed by using Chromatin Immunoprecipitation Kit (Active Motif) according to manufacturer's protocol. Formaldehyde cross-linked chromatin was immunoprecipitated with anti-p63, anti-p53 or normal IgG antibodies as indicated. Eluted DNA was PCR amplified with primers specific for VDR and 14-3-3s promoter. 14-3-3s promoter amplification was used as a positive control for both p63 and p53. Immunoprecipitation was performed using rabbit polyclonal H-137 specific for p63, rabbit polyclonal FL393 specific for p53 and normal rabbit IgG antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). PCR amplification was performed by using Pfx polymerase (Invitrogen, Carlsbad, CA) and the following PCR conditions. For VDR, 38 cycles were performed each consisting of 30 s at 941C, 30 s at 581C and 45 s at 681C; for 14-3-3s, 38 cycles were performed each consisting 30 s at 941C, 30 s at 581C and 45 s at 681C. Primers used for amplification are as follows: VDR, forward 5 Identification of vitamin D receptor as a target of p63 R Kommagani et al activity. Co-transfection of p53 did not upregulate the À631/À585 reporter activity (data not shown). The complexity of the p63 binding sites would require further analysis in order to precisely map the p63 binding sites. Nonetheless, our preliminary analysis suggests that potential p63 binding sites reside within the VDR promoter region.
Next, we wanted to investigate whether upregulation of VDR by p63 results in differentiation in SaoS2 (osteosarcoma) cells (Sasaki et al., 2005) . SaoS2 cells transiently transfected with p63g showed a significant increase in number of cells with elongated cytoplasmic processes and flattened fibroblastic appearance. In contrast SaoS2 cells transfected with p53 or p63g (R279H) mutant showed a more rounder appearance. Approximately 63% of the cells transfected with p63 showed an altered morphology compared to 23 and 12% of the cells transfected with p53 or p63g (R279H) mutant, respectively (Figure 4c ). This indicates that cells might be undergoing differentiation in the presence of p63g. The osteoblast differentiation marker Osteopontin (OPN) has a putative vitamin D receptor binding regions (VDRE) within its promoter region and has been shown to be a direct target of VDR (Noda et al., 1990; Bikle, 1992; Koszewski et al., 1996) . In addition, core binding factor alpha 1/runt related transcription factor 2 (Cbaf1/ RUNX2) and osteocalcin (OCN) have also been shown to be markers of osteogenesis (Wagner and Karseny, 2001; Lian and Stein, 2003) . The expression of OPN, OCN and CBFA1/RUNX2, markers of osteogenesis, was determined in SaoS2 cells transfected with p63, p53 or p63g (R279H) mutant. As shown in Figure 4d , while we observed an increase in OPN, OCN, RUNX2 and VDR mRNA levels in SaoS2 cells transfected with p63g, p63g (R279H) mutant and p53 were unable to induce expression of OPN, OCN, RUNX2 and VDR. Detection of p21 mRNA levels was used as positive control for p63 and p53. The absence of both VDR and osteogenic differentiation marker expression in SaoS2 cells transfected with p53 or p63g (R279H) suggests that activation of VDR is required for effective differentiation in SaoS2 cells. Expression of OPN is also affected by treatment with VD. We, therefore, studied expression of OPN in cells transfected with control vector or p63g and treated with VD. Although OPN induction was increased in control cells treated with VD, cells transfected with p63g and treated with VD caused a synergistic effect on OPN expression (Figure 4e ). This suggests that p63 further sensitizes the cells to the VD treatment by inducing VDR.
VD and its analogues are used as chemotherapeutic agents for the treatment of prostate cancer and primarily functions through the activation of the VDR. This is an important finding since VDR induces differentiation and antiproliferative activities in various cancer cell lines including prostate cancer. p63 can increase sensitivity to the VD treatment through upregulation of genes involved in regulation of the VDR pathway. Additionally the levels of p63 have been shown to be modulated by chemotherapeutic drugs. Thus increasing the levels of TAp63 with chemotherapy could also lead to an increase in VDR expression and subsequently enhance the effectiveness to the VD analogues. Another possible mechanism by which p63g-mediated VDR expression may play a role in cancer could be through regulation of b-catenin pathway (Patturajan et al., 2002) . VDR activation has been shown to induce differentiation by inhibition of the b-catenin signaling pathway (Palmer et al., 2001) . p63 isoforms containing the transactivation domain induces VDR expression which in turn can induce E-Cadherin that can bind up b-catenin. Deregulation of b-catenin, either by direct mutation or by defects in interacting pathways/regulators can result in cytoplasmic accumulation and nuclear translocation and often leads to cancer. Thus, p63 may exert differential effects on the b-catenin pathway possibly through regulation of the VDR pathway and might represent a novel pathway by which p63 can regulate genes associated with morphogenesis and differentiation.
